This item was submitted to [Loughborough's Research Repository](#) by the author.
Items in Figshare are protected by copyright, with all rights reserved, unless otherwise indicated.

A meta-analysis of biological variation in blood-based therapy as a precursor to bio-manufacturing

PLEASE CITE THE PUBLISHED VERSION

<http://dx.doi.org/10.1016/j.jcyt.2016.01.011>

PUBLISHER

Elsevier (© International Society for Cellular Therapy)

VERSION

AM (Accepted Manuscript)

PUBLISHER STATEMENT

This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at:
<https://creativecommons.org/licenses/by-nc-nd/4.0/>

LICENCE

CC BY-NC-ND 4.0

REPOSITORY RECORD

Thurman-Newell, Jamie, Jon Petzing, and David Williams. 2019. "A Meta-analysis of Biological Variation in Blood-based Therapy as a Precursor to Bio-manufacturing". figshare. <https://hdl.handle.net/2134/21083>.

1
2
3
4 A Meta-analysis of Biological Variation in Blood-based Therapy
5 as a Precursor to Bio-Manufacturing.
6
7

8 Jamie. A. Thurman-Newell, Jon N. Petzing, David J. Williams
9

10 Healthcare Engineering Group, Centre for Biological Engineering, Holywell Park,
11 Loughborough University, LE11 3TU, UK.
12
13

14 J.Thurman-Newell@lboro.ac.uk
15
16

17 Funding for this work was provided by a UK EPSRC Grant (EP/FS00491/1) as part of the
18 Doctoral Training Centre for Regenerative Medicine
19

20 [Keywords: HSCT, biological variation, blood, quality control, process design]

21 **Abstract**

22 Currently cellular therapies, such as haematopoietic stem cell transplantation (HSCT), are
23 produced at a small scale on case-by-case basis, usually in a clinical or near-clinical setting.
24 Meeting the demand for future cellular therapies will require a robust and scalable
25 manufacturing process that is either designed around, or controls the variation associated with
26 biological starting materials.

27 Understanding variation requires both a measure of the allowable variation (that does not
28 negatively affect patient outcome) and the achievable variation (with current technology).
29 The prevalence of HSCT makes it an ideal case study to prepare for more complex biological
30 manufacturing with more challenging regulatory classifications.

31 A systematic meta-analysis of the medical literature surrounding HSCT has been completed
32 of which the key outcomes are;

- 33 • The range of transplanted CD34+ cells / kg can be up to 6 orders of magnitude around
34 the median for allogeneic procedures and 4 orders of magnitude for autologous
35 procedures
- 36 • No improvement in variation encountered over a period of thirty years
- 37 • As study size increases the amount of variation encountered increases

38 A more detailed, stratified source from a controlled single site clinical centre is required to
39 further define a control strategy for the manufacture of biologics.

1.0 Introduction

Cellular therapies are currently produced in small batches, typically in a clinical setting, under special legislation such as the European Hospital Exemption Clause and the FDA's Investigational New Drug Exemption. These small batch sizes will struggle to meet future demand, so an appropriate bio-manufacturing process is likely to be required to replace some or all of the currently predominately manual processing. A quality by design approach to process control that is based around, or controls, the variation inherent to biological starting materials, is anticipated as being a key prerequisite to bio-manufacturing at scale and an ongoing challenging prospect for entrepreneurs, manufacturers and regulators alike.

Understanding biological variation requires both a measure of the;

- Allowable variation, that does not impinge on safety or efficacy
- Achievable variation, as a result of our current level of technology and skill

The allowable variation is based upon the specification, set by the prescriber, which details the limits of variation that a product must remain within to avoid negatively affecting patient outcome. The achievable variation is based upon the tolerance of the process / machine, set by engineers, which is based upon the ability of the process to cope with this variation. Furthermore, an understanding of the variation in the starting material, as a result of the patient/donor population, the isolation techniques and the previous conditioning regimes, is required. Together, this knowledge will ultimately inform strategies to account for this variation, including how to address the issue of comparability - demonstrating that the process remains the same after a change, which can include distributed manufacture at multiple locations, whilst still remaining cost-effective¹ and within tolerance.

Control of variation will facilitate the production of a consistent, comparable product, with a known efficacy, at scale. This has the potential to increase the quality of the product (therefore maximising patient longevity and quality of life), or maintain the quality of the product but at a reduced cost².

2.0 Exemplar

Haematopoietic stem cell therapy (HSCT) is one of the few cellular therapies currently in routine use³, with a proven historical track record, and is relatively well established worldwide. The therapeutic potential of this therapy originates from the haematoepoetic progenitor cells - a self-renewing precursor cell that has the potential to become a number of specialised cell and tissues. HSCT utilises the unique properties of these cells, isolated from peripheral blood, bone marrow or cord blood for clinical applications such as the revivification of a patient's bone marrow following potent chemotherapy or radiotherapy.

The prevalence of HSCT is one of the reasons it was chosen as an exemplar to benchmark the variation encountered in cellular therapies. It is a secondary therapeutic (the chemotherapy or radiotherapy is the primary therapeutic) but it occupies a unique regulatory niche in that it is 'minimally manipulated', so has the potential as a case study to inform process design for more complex bio-manufacturing of products that are more than minimally manipulated, and fall into more challenging regulatory classifications such as Advanced Therapy Medicinal Products (ATMPs)⁴.

3.0 Variation Meta-Analysis Methodology

The objective of this research was to determine the baseline extent of variation encountered for HSCT, under the practise of medicine, because this therapy is manufactured and applied within a clinical setting. This research expands upon previous work⁵, by adding greater resolution, and examining the challenge from a nascent bio-manufacturing perspective.

This analysis was designed to; examine the medical literature on HSCT for collected / transplanted cell metrics (such as total nucleated cell count or CD34+ cell count – a cell surface marker present on haematopoietic stem cells), examine and report the extent of variability in these metrics within and between these studies, and if sufficient detail was present, correlate this variation with donor / patient metrics, processing methodology and clinical centre, amongst other variables.

This work is intended to compliment a clinical case study by providing a platform for discussion between stakeholders, and a global picture to compare with single centre study

data thus providing a demonstration of the current 'state of control'. The research presented here focuses on the results of the literature meta-analysis.

Online databases and health resources (Pubmed and Web of Knowledge) were used to search the literature for a number of pre-determined keywords, medical search headings (MeSH) and publication dates. Articles were restricted to English language, unless a native translation was provided, and only refereed journals were used (conference proceedings, for example, were excluded).

The abstracts of the resultant studies were then screened for the likelihood of containing applicable data, such as clinical trials or outcomes studies. Eligible publications were then obtained in full and stored locally, and given a unique identifier that could be linked to the database for future reference. These publications were then manually examined for patient, donor and graft measurements. A pre-determined checklist of measurements had been previously created for this task, from mind-mapping and stakeholder discussion (**see Table 1**). A number of primary characteristics, such as the presence of TNC count or CD34+ cell count, were mandatory for studies to pass through to the data collection stage. At this stage, data was transferred and stored next to the identification number within a database. MS Excel and IBM SPSS 22.0 (New York) were used for the analysis.

4.0 Results

5,458 peer-reviewed journal articles (previously 3,190⁵), between 1980 and 2015, were identified. This resulted in 269 (previously 126⁵) articles that contained 491 observations included donor, methodological and graft variables.

Variation was measured from reported cell metrics, of which total nucleated cell count (TNC) and CD34+ cell count were most prevalent. These were reported as TNC / kg and CD34+ cells / kg patient bodyweight. Interquartile ranges were often provided *in lieu* of range data within articles, but were not recorded as they are not representative of the true value of biological disparity and avoid up to 50% of possible variation. Cord blood and paediatric datapoints were removed (due to low incidence level) so this dataset represents adult bone marrow and peripheral blood derived material only. It should be noted that in certain figures the x axis title refers to the unique identifying number given to each valid

study, however data in each of these figures is discontinuous and consequently explicit numbering has been omitted.

Biological metrics, such as CD34+ cell count, were heavily negatively skewed, probably due to the presence of these cells being host-state dependant or the minimum collection criteria. Non-parametrically distributed data requires a different statistical approach – for example Spearmans Rank Order Correlation (SROC) was used for bivariate analysis, rather than the traditional Pearson Product-Moment Correlation used in normally distributed data. The value for SROC refers to the strength and direction of the correlation, the *p*-value refers to the statistical significance of the test, and the *n*-value refers to the number of data-points included in the analysis.

The results of the meta-analysis are presented as a summary in italics which prefixes the explanation that follows.

4.1 Overall Variation

Under the practise of medicine, the variation currently encountered in HSCT (represented in this sub-population) can be between one and four orders of magnitude of the median reported amount.

The range of both collected CD34+ cells (cCD34) and transplanted CD34+ cells (tCD34) was calculated for each study sample. An open-high-low-close (OHLC) chart (**Figure 1**) was used to plot each representative samples' median, minimum and maximum cCD34, and tCD34. This format was used for biological data because it is a visually succinct method of demonstrating the extent of variation with respect to the median, and with other studies. This figure represents the overall variation for (a) cCD34 and (b) tCD34 (*n* = 106 and *n* = 303, respectively). Each central point represents the median value reported within a particular study, and the vertical lines are indicative of the ranges reported. Point 1b(i) on Figure 1 exhibits no obvious characteristics that would differentiate itself from other studies (as paediatric donors or cord-blood sourced transplants have already been excluded).

A number of studies have reported a minimum of zero collected or transplanted cell counts which are very particular extremes. It is unlikely this is a true value of sero,

but rather that insufficient cells were mobilised and was deemed unviable in the study. These values, as much as they must be considered as a representation of an individuals' personalised medicine, skew the overall analysis of variation considerably. Including the zero values the variation is up to 9 orders of magnitude, whilst excluding them the variation is up to 6 orders of magnitude. For this discussion only quantifiable collected / transplanted cell counts have been used – stating the variation can be up to 9 orders of magnitude because of these zero values is clearly misleading.

4.2 Stratification of the Overall Variation into Collected and Transplanted

Allogeneic-derived material can vary up to 6 orders of magnitude of the median cell count, whilst autologous-derived material can vary up to 4 orders of magnitude.

Figures 2 and 3 stratify cCD34 / kg / study and tCD34 / kg / study into transplant type and cell source. Only autologous peripherally sourced material was recorded with any magnitude in Figure 2. The ranges between extremes, and the variation in orders of magnitude of the median value, have been annotated on the diagram accordingly.

The variation in cCD34 is up to four orders of magnitude of the median value (3.00×10^5 cells / kg to 2.98×10^8 cells / kg, $n = 86$). There was insufficient data to stratify between autologous and allogeneic.

The variation in tCD34 is;

- up to six orders of magnitude of the median value for allogeneic therapy (1.00×10^3 cells / kg to 1.21×10^9 cells / kg, $n = 188$)
- up to four orders of magnitude of the median value for autologous therapy (6.00×10^4 cells / kg to 3.00×10^8 cells / kg, $n = 110$)

As a result, autologous therapy appears considerably more manageable from a variation perspective than allogeneic therapy. Further stratification will be required to determine the reason for the greater amount of variation present within allogeneically sourced material.

4.3 Variation as a Function of Time

Overall, there has been limited improvement (or apparent drive to improve) in the community's ability to control variation over a thirty year time period.

Figure 4 represents the range of (a) cCD34 and (b) tCD34, measured against the year in which the study commenced. This is the stage where the protocols are established and therefore represent the technology / methodology typical of the time. The relative lack of data points between 2010 and 2015 has been attributed to studies in progress, and not yet reported. The correlation between range of CD34+ cells / kg / study and study year was examined using SROC, for both collected and transplanted cells, to alleviate the Cluster Illusion from data interpretation, between 1980 and 2015. The application of SROC was confirmed by visual inspection and a Shapiro-Wilks normality test ($p > 0.05$). Preliminary analysis showed the relationship to be monotonic.

There was a weak statistically significant correlation between range of cells, and time for both collected ($SROC = -0.295, p < 0.003$) and transplanted cells ($SROC = -0.178, p < 0.003$). There are a number of other factors that may contribute towards a correlation rather than just starting year (such as incremental technology advances, or institutional experience), however improvement was expected. Additionally the number of unknowns (of which some are summarised in Section 5: *Meta-Analysis Limitations*) are enough that any correlation can be argued to be insignificant or circumstantial.

4.4 Variation by Country of Study

There is insufficient resolution to discern any specific advantage in terms of variation between any clinical centre or country.

This meta-analysis contains observations from 32 different countries and by multinationals, which are represented by 143 clinical centres. A Pareto Analysis was previously carried out on the meta-analysis database to discern the leading contributors within this dataset. The Pareto Rule – often called the 80/20 Rule – refers to the observation that 80% of the effect is due to 20% of the factors. This identified ten countries that had significant presence and were subsequently used to

plot another OHLC chart (**Figure 5**). Only tCD34 has sufficient data-points within the dataset to plot with significance.

For each country, the number of centres contributing towards the result has been annotated. It is difficult discern differences between countries without much greater resolution, because each of these centres will probably operate under different practises / equipment / staff, and target different indications and patients. However, there is sufficient evidence that biological variation is a global concern.

4.5 Variation as a Function of Study Size

As the number of donor / patients involved in a study increased, the amount of variation also increased.

Figure 6 is a stratified scatter diagram of the range of tCD34 / kg / study against the number of patients / donors in the study. SROCs were carried out for each subsection and have been included in this diagram (a – f). These statistically significant correlations demonstrate that as the size of the study increases (and therefore the number of donors and products involved) the total variation per study increases. From a variation perspective this not only indicates that the current lab-based production methods find it increasingly difficult to process large volumes of product in a consistent manner, but will most probably be unsuitable for large scale production of a future therapeutic.

5.0 Meta-Analysis Limitations

Due to the disparate and aggregated nature of how public data is reported and subsequently collected in this study, a number of limitations must be considered when regarding these results.

- *Outliers.* In biological manufacturing, ‘outliers’ can be representative of the heterogeneity of an individual’s biological state (and/or their personalised medicine), so cannot be disregarded.
- *Sampling Variation.* There may be an element of author bias which may have resulted in data-containing studies being overlooked, but given the overall

spread of the data the authors do not anticipate any significant shift in statistical behaviour.

- *Duplicate Data.* Due to conglomerate groups, such as the European Bone Marrow Transplant Group (EBMT), there is a risk of overlapping data. This is a problem that using dedicated raw data will not encounter.
- *Patient versus Donor Weight.* cCD34 and tCD34 were reported as cells per kg of patient bodyweight, ideally they would have to be first normalised to donor bodyweight – (in autologous therapy, this is not an issue because the patient is also the donor) –for allogeneic therapy this would be an instance of adding distance from the true value.
- *Paediatric Analysis.* This meta-analysis contained a total of 18 paediatric donor based studies and therefore a separate analysis regarding children has not been made, or a comparison between adult and paediatric cCD34 and tCD34. However importantly, autoimmune disease, inherited metabolic disorders and gene therapy are all prime targets for paediatric therapy⁶ and an understanding of paediatric variation would be beneficial.
- *Mobilisation / Conditioning Regime.* These are difficult to quantify because they vary on a case-by-case basis, in terms of dosage, regime, drugs, clinician⁷ and a combination of these. Additionally, details were not uniformly reported. These regimes are crucial factors⁸ in the content and quality of the starting material for HSCT and proper characterisation and stratification is vital to a better understanding.
- *Apheresis / Aspiration Processes.* Details regarding the instrumentation used for apheresis, flow rates, number of procedures or extractions were rarely reported. Furthermore it is not clear from the literature whether cCD34 is taken from the total collected cell count, or from a particular stage – or how many extractions were used. It is common clinical practise to pool individual products but it is unclear which (if any) of the reported metrics are pooled products. The number of collections is also a factor in addition to patient health⁹.

- 268 • *Cryopreservation and Transport.* It is accepted that cryopreservation causes
269 losses in TNC, viability and CD34+ cell numbers¹⁰ but it is unclear as to whether
270 this loss, is a contributing factor towards variation.
- 271 • *Multiple Centres.* There are a number of centres with multiple observations
272 within the dataset, but not sufficient numbers to make meaningful statistical
273 observations regarding the variation between and within centres. The use of raw
274 data from clinical centres would be needed to allow this comparison.
- 275 • *Raw Materials versus Starting Materials.* Another variable are additional
276 chemicals added to the product. The UK MHRA has defined these as 'raw
277 materials', whilst the biological component is the 'starting material' and it is
278 important to understand the effect both have on each other and the process.
- 279 • *Indication.* Patient disease state was too generalised to stratify from the dataset.

6.0 Conclusion and Summary

This meta-analysis of publically available data has been developed to provide a broad-scope demonstration of the challenge that biological input variation imposes on the potential for controlling large scale bio-manufacture and will impose when manufacturing Advanced Therapy Medicinal Products. The primary output from this analysis are results that represent the extent of biological variation in both collected and transplanted material for a clinical sub-population.

This meta-analysis has determined that;

- The current variation encountered under the practice of medicine for haematopoietic stem cell therapy can be up to six orders of magnitude of the median dose. This level of variation would be unmanageable from a bio-manufacturing perspective.
- Comparing the ranges of collected and transplanted CD34+ cells over time, there is little evidence to suggest an improvement in the community's ability to control the variation in HSCT over the last three decades.
- There is a weak negative correlation between collected CD34+ cells and study start year, which may represent improvement in apheresis technology, but the range of transplanted CD34+ cells remains inconsistent over the thirty years. This has potential implications for comparable efficacy, patient outcome, and mode of action.

It is clear that to make the next decisions on an appropriate bio-manufacturing strategy, a stratifiable data source with greater resolution will be required; such as patient databases and centre-specific clinical records. Without this raw data, quantification of sources and extent of variation contributed by each variable will remain informed speculation.

Consequently the next step in this research is the acquisition and analysis of high quality datasets from clinical petitioned national health sources, where the data represents individual cases, not summaries. This will allow stratification of the contributions of variables such as donor age or weight, process parameters and indication and an increased rigour and quality in the reported results. This will also allow access to absolute numbers of cells per collection / product. Additionally, using datasets from specific centres will allow

309 normalisation of the variation with respect to centre specific factors, such as geographical,
310 surgical, clinical and operator variation, because these should remain constant within a
311 single centre.

312 Variation cannot be eliminated completely, but it will need to be brought to a state where
313 the differences in the product do not negatively affect patient outcome, and is a key step in
314 establishing product specifications and achievable manufacturing tolerance ranges. To meet
315 this challenge, cross-disciplinary collaboration between medical and engineering fields will
316 be crucial¹¹; sharing their combined experience will enable strategies required to
317 accommodate and control variation for production to accommodate large numbers of
318 patients – either in large volume in concentrated facilities, or smaller volumes at multi-site
319 centres¹.

320 **7.0 Acknowledgements**

321 Competing interests: the authors have no competing interests. Funding for this work
322 was provided by a UK EPSRC Grant (EP/FS00491/1) as part of the Doctoral Training
323 Centre for Regenerative Medicine. Special thanks to Professor Nick Medcalf and Dr
324 Paul Hourd for their input.

325

326 **8.0 List of Figures**

327 Table 1: Meta-Analysis Search and Retrieval Methodology

328 Figure 1 Range of CD34+ Cell Count / kg / Study for;

329 a) Collected Cells

330 b) Transplanted Cells

331 Figure 2 Range of CD34+ Cell Count / kg / Study for;

332 Autologous Peripheral-sourced transplants

333 Figure 3 Variation in Transplanted CD34+ Cell Counts / kg / Study stratified into;

334 a) Autologous peripheral

335 b) Autologous bone marrow

336 c) Autologous mixed source

337 d) Allogeneic peripheral

338 e) Allogeneic bone marrow

339 f) Allogeneic mixed source

340 Figure 4 Range of CD34+ Cells / kg / Study Against Time stratified into;

341 a) Collected Cells

342 b) Transplanted Cells

343 Figure 5 Range of transplanted CD34+ cells / kg / Study between Countries

344 Figure 6 Range of transplanted CD34+ cells / kg / Study against Study Size stratified
345 into;

346 a) Autologous peripheral

347 b) Autologous bone marrow

348 c) Autologous mixed source

349 d) Allogeneic peripheral

350 e) Allogeneic bone marrow

351 f) Allogeneic mixed source

9.0 References

1. Hourd P, Ginty P, Chandra A, Williams DJ. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: Regulatory and scientific challenges for comparability. *Cytotherapy*. 2014;16(8):1033-1047. doi:10.1016/j.jcyt.2014.03.005.
2. Escalante EJ. Quality and Productivity Improvement: A Study of Variation and Defects in Manufacturing. *Qual Eng*. 1999;11(3):427-442. doi:10.1080/08982119908919259.
3. Martin P. The Market Opportunity. In: *Building A Viable Regenerative Medicine Industry - A Guide for Stakeholders*. University of Loughborough; 2010:13-20.
4. Hourd P, Chandra A, Medcalf N, Williams DJ. Regulatory challenges for the manufacture and scale-out of autologous cell therapies. In: *StemBook*.; :1-13. doi:10.3824/stembook.1.96.1.1.
5. Thurman-Newell JA, Petzing JN, Williams DJ. Quantification of biological variation in blood-based therapy - a summary of a meta-analysis to inform manufacturing in the clinic. *Vox Sang*. 2015;109(4):394-402. doi:10.1111/vox.12288.
6. Domen J, Gandy K, Dalal J. Emerging uses for pediatric hematopoietic stem cells. *Pediatr Res*. 2012;71(4 Pt 2):411-7. doi:10.1038/pr.2011.55.
7. Auerbach AD, Landefeld CS, Shojania KG. The tension between needing to improve care and knowing how to do it. *N Engl J Med*. 2007;357:608-613. doi:10.1056/NEJMs070738.
8. Hopman RK, DiPersio JF. Advances in stem cell mobilization. *Blood Rev*. 2014;28(1):31-40. doi:10.1016/j.blre.2014.01.001.
9. Hung Y-C, Bauer J, Horsley P, Waterhouse M, Bashford J, Isenring E. Changes in nutritional status, body composition, quality of life, and physical activity levels of cancer patients undergoing autologous peripheral blood stem cell transplantation. *Support Care Cancer*. 2013;21(6):1579-86. doi:10.1007/s00520-012-1698-y.
10. Winter JM, Jacobson P, Bullough B, Christensen AP, Boyer M, Reems J-A. Long-term effects of cryopreservation on clinically prepared hematopoietic progenitor cell products. *Cytotherapy*. 2014;16(7):965-75. doi:10.1016/j.jcyt.2014.02.005.
11. Marshall M, Pronovost P, Dixon-Woods M. Promotion of improvement as a science. *Lancet*. 2013;381(9864):419-421. doi:10.1016/S0140-6736(12)61850-9.

Primary Study Characteristics	Secondary Study Characteristics	Tertiary Study Characteristics
Number of Donors	Donor Mobilisation Drug	Named Collection Equipment
Donor Gender	Donor Mobilisation Regime	Named Processing Equipment
Donor Age*	Day of Aspiration / Apheresis	Named Analytical Equipment
Donor Weight (kg)*	Study Start and End Year	CD34 Elucidaion Method
Donor Ethnicity	Number of Centres involved in Study	Number of Aspirations / Apheresis procedures per donor
Number of Patients	Country of Study	Apheresis flow rate used (mL/min)
Patient Gender	Patient Indication	Target Apheresis Volume (mL)
Patient Age*	Patient Prior Medication	Duration of Apheresis
Patient Weight (kg)*	Patient Prior Stem Cell Therapy (Yes / No)	Target Apheresis CD34+ Count
Patient Ethnicity		Number of times Donor Complete Blood volume was processed
Patient Conditioning		Number of Grafts / Transfusions per patient
Autologous or Allogeneic Therapy		Collection aims for TNC, MNC and CD34+ cell populations
Source of Stem Cells (marrow, peripheral, cord or COLLECTED TNC, MNC, CD34+, CFU-GM and viability (mean, median, standard deviation, upper and lower ranges)		Volume of Collection (mL/kg)
TRANSPLANTED TNC, MNC, CD34+, CFU-GM and viability (mean, median, standard deviation, upper and lower ranges)		
* At time of procedure		